Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma

Intervirology

Volumn 48, Issue 1, 2005, Pages 64-70

  Sakaguchi, Yasuhiro ^a   Kudo, Masatoshi ^a   Fukunaga, Toyokazu ^a   Minami, Yasunori ^a   Chung, Hobyung ^a   Kawasaki, Toshihiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Interferon; Intrahepatic recurrence; Radiofrequency ablation

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALAISE; MALE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SIDE EFFECT; THROMBOCYTE COUNT; VIROLOGY;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE;

EID: 17244379463     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082097     Document Type: Article

References (29)

1. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 2000;340:745-750.
2. Okuda K, Fujimoto I, Hanai A, Urano Y: Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987;47:4967-4972.
3. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Hamamura K, Imai Y, Yoshida H, Shiina S, Omata M: Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus: An analysis of 236 consecutive patients with a single lesion. Hepatology 2000;32:1216-1223.
4. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S: Randomized trial of effects of interferon-alpha on incidences of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
5. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-1130.
6. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, Hino K, Okita K: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998;27:1394-1402.
7. Shindo M, Ken A, Okuno T: Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer 1999;85:1943-1950.
8. Wen YL, Kudo M, Zheng RQ, Minami Y, Chung H, Suetomi Y, Onda H, Kitano M, Kawasaki T, Maekawa K: Radiofrequency ablation of hepatocellular carcinoma: Therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. Am J Roentgenol 2003;181:57-63.
9. Kudo M: Contrast harmonic ultrasound is a breakthrough technology in the diagnosis and treatment of hepatocellular carcinoma. J Med Ultrasonics 2001;28:79-81.
10. Ding H, Kudo M, Onda H, Suetomi Y, Minami Y, Chung H, Kawasaki T, Maekawa K: Evaluation of post-treatment response for hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: Comparison with dynamic CT. Radiology 2001;221:721-730.
11. Ding H, Kudo M, Onda H, Suetomi Y, Minami Y, Maekawa K: Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma. Am J Roentgenol 2001;221:721-730.
12. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL: Treatment of chronic hepatitis C with recombinant interferon alpha: A multicancer, randomized controlled trial. N Engl J Med 1989;321:1501-1506.
13. Suou T, Mitsuda A, Koda M, Matsuda H, Maruyama S, Tanaka H, Kishimoto Y, Kohno M, Hirooka Y, Kawasaki H: Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: A pilot study. Hepatol Res 2001;20:301-311.
14. Sun HC, Tang ZY: Preventive treatments for recurrence after curative treatments for recurrence after curative resection of hepatocellular carcinoma. A literature review of randomized control trials. World J Gastroenterol 2003;9:635-640.
15. Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, Liu YK, Liu KD, Tang ZY: Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 2003;7:587-594.
16. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, Liaw YF: Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004;100:376-382.
17. Kudo M: Local ablation therapy for hepatocellular carcinoma: current status and future perspective. J Gastroenterol 2004;39:205-214.
18. Uenishi T, Kubo S, Hirohashi K, Tanaka H, Shuto T, Yamamoto T, Tamori A, Hai S, Kinoshita H, Nishiguchi S: Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus related hepatocellular carcinoma. Hepatol Res 2002;24:404-412.
19. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002;89:418-422.
20. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Takemura S, Yamamoto T, Ikebe T, Wakasa K, Shiomi S, Kinoshita H: Influence of previous interferon therapy on recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Jpn J Cancer Res 2001;92:59-66.
21. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Ann Intern Med 2001;134:963-967.
22. Kubo S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Ikebe T, Yamamoto T, Wakasa K, Nishiguchi S, Kuroki T, Kinoshita H: Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. World J Surg 2000;24:1559-1565.
23. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H: Interferon-beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-232.
24. Ikeda K, Arase Y, Kobayashi M, Saitoh S, Someya T, Hosaka T, Suzuki Y, Suzuki F, Tsubota A, Akuta N, Kumada H: Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: A long-term cohort study of 892 patients with viral cirrhosis. J Gastroenterol 2003;38:865-876.
25. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T: Integration of interferon-α/ β signaling to p53 responses in tumor suppression and antiviral defence. Nature 2003;424:516-523.
26. Sangfelt O, Erickson S, Castro J, Heiden T, Gustafsson A, Einhorn S, Grander D: Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CDI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 1999;18:2798-2810.
27. Lindahl P, Leary R, Gresser I: Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA 1972;69:721-725.
28. Trinchieri G, Santoli D, Koprowski H: Spontaneous cell-mediated cytotoxicity in humans. J Immunol 1978;120:1849-1855.
29. Folkman J, Ingber D: Inhibition of angiogenesis. Semin Cancer Biol 1992;3:89-96.